Accelerate Diagnostics logo

Accelerate DiagnosticsNASDAQ: AXDX

Profile

Sector:

Healthcare

Country:

United States

IPO:

07 April 1994

Next earnings report:

08 November 2024

Last dividends:

N/A

Next dividends:

N/A
$44.52 M
-90%vs. 3y high
33%vs. sector
-vs. 3y high
-vs. sector
-100%vs. 3y high
10%vs. sector
-90%vs. 3y high
52%vs. sector

Price

after hours | 10 min ago
$1.88+$0.05(+2.73%)

Dividend

No data over the past 3 years
$2.99 M$3.02 M
$2.99 M-$11.59 M

Analysts recommendations

Institutional Ownership

AXDX Latest News

Accelerate Diagnostics Scheduled Call to Review 2024 Third Quarter Results
prnewswire.com25 October 2024 Sentiment: -

TUCSON, Ariz. , Oct. 25, 2024 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ: AXDX) announced that management will host a conference call Thursday, November 7, 2024, at 4:30 p.m.

Accelerate Diagnostics Stock Down Despite FDA Clearance for Arc System
zacks.com01 October 2024 Sentiment: POSITIVE

AXDX's Arc system gains FDA clearance, automating blood culture prep for faster microbial ID, improved sepsis outcomes and reduced hospital costs.

Accelerate Diagnostics Announces FDA Clearance of its Accelerate Arc™ System
prnewswire.com30 September 2024 Sentiment: POSITIVE

An automated platform designed to fight against Sepsis and Antimicrobial Resistance (AMR) Enables rapid, automated microbial identification on the Bruker MALDI Biotyper® CA System directly from positive blood culture samples TUCSON, Ariz. , Sept. 30, 2024 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ: AXDX), an innovator of rapid in vitro diagnostics, announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance of the Accelerate Arc system and BC kit, an innovative, automated positive blood culture sample preparation platform, for use with Bruker's MALDI Biotyper® CA  System (MBT-CA System) and MBT-CA Sepsityper® software extension.

Accelerate Diagnostics (AXDX) Completes WAVE Pre-Clinical Trial
zacks.com14 August 2024 Sentiment: POSITIVE

Accelerate Diagnostics (AXDX) is confident about WAVE product design and the system's capabilities after the successful completion of the pre-clinical trial.

Accelerate Diagnostics, Inc. (AXDX) Q2 2024 Earnings Call Transcript
seekingalpha.com10 August 2024 Sentiment: POSITIVE

Accelerate Diagnostics, Inc. (NASDAQ:AXDX ) Q2 2024 Earnings Conference Call August 8, 2024 4:30 PM ET Company Participants Laura Pierson - Investor Relations Officer Jack Phillips - President and CEO David Patience - Chief Financial Officer Conference Call Participants Andrew Brackmann - William Blair Operator Good day. And welcome to the Accelerate Diagnostics Incorporated Second Quarter 2024 Results Conference Call.

Accelerate Diagnostics (AXDX) Reports Q2 Loss, Misses Revenue Estimates
zacks.com08 August 2024 Sentiment: NEUTRAL

Accelerate Diagnostics (AXDX) came out with a quarterly loss of $0.50 per share versus the Zacks Consensus Estimate of a loss of $0.55. This compares to loss of $2.36 per share a year ago.

Accelerate Diagnostics Reports Second Quarter 2024 Financial Results
prnewswire.com08 August 2024 Sentiment: NEUTRAL

TUCSON, Ariz. , Aug. 8, 2024 /PRNewswire/ -- Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced financial results for the second quarter ended June 30, 2024.

Accelerate Diagnostics Scheduled Call to Review 2024 Second Quarter Results
prnewswire.com08 August 2024 Sentiment: NEUTRAL

TUCSON, Ariz. , Aug. 8, 2024 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ: AXDX) announced that management will host a conference call today, Thursday, August 8, 2024, at 4:30 p.m.

Will Accelerate Diagnostics (AXDX) Report Negative Q1 Earnings? What You Should Know
Zacks Investment Research02 May 2024 Sentiment: NEGATIVE

Accelerate Diagnostics (AXDX) lacks the necessary elements for a potential earnings surprise in its upcoming report. Be ready for the expected results.

Accelerate Diagnostics Inc. (AXDX) Q4 2023 Earnings Call Transcript
Seeking Alpha28 March 2024 Sentiment: POSITIVE

Accelerate Diagnostics Inc. (AXDX) Q4 2023 Earnings Call Transcript

  • 1(current)

What type of business is Accelerate Diagnostics?

Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms. It also provides the Accelerate PhenoTest, a test kit for the system, which provides identify and antibiotic susceptibility testing results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk. The company was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012. Accelerate Diagnostics, Inc. was incorporated in 1982 and is headquartered in Tucson, Arizona.

What sector is Accelerate Diagnostics in?

Accelerate Diagnostics is in the Healthcare sector

What industry is Accelerate Diagnostics in?

Accelerate Diagnostics is in the Medical Devices industry

What country is Accelerate Diagnostics from?

Accelerate Diagnostics is headquartered in United States

When did Accelerate Diagnostics go public?

Accelerate Diagnostics initial public offering (IPO) was on 07 April 1994

What is Accelerate Diagnostics website?

https://acceleratediagnostics.com

Is Accelerate Diagnostics in the S&P 500?

No, Accelerate Diagnostics is not included in the S&P 500 index

Is Accelerate Diagnostics in the NASDAQ 100?

No, Accelerate Diagnostics is not included in the NASDAQ 100 index

Is Accelerate Diagnostics in the Dow Jones?

No, Accelerate Diagnostics is not included in the Dow Jones index

When was Accelerate Diagnostics the previous earnings report?

No data

When does Accelerate Diagnostics earnings report?

The next expected earnings date for Accelerate Diagnostics is 08 November 2024